BioLine RX Ltd (TA:BLRX) — Stock Price
BioLine RX Ltd (TA:BLRX) is currently trading at ILA1.40 ILA, down 12.50% today. Over the past 52 weeks, shares have ranged between ILA1.20 and ILA2.30. This page tracks BioLine RX Ltd's live share price on the TA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see BLRX market cap overview.
BioLine RX Ltd (BLRX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks BioLine RX Ltd's daily closing share price and trading volume on the TA exchange over the past year, giving a clear view of recent price momentum and liquidity.
BioLine RX Ltd Income Statement — Revenue, Profit & Earnings by Year
BioLine RX Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ILA28.94 Million | ILA4.80 Million | ILA0.00 | ILA0.00 | ILA0.00 |
| Cost of Revenue | ILA9.26 Million | ILA3.69 Million | ILA0.00 | ILA0.00 | — |
| Gross Profit | ILA19.68 Million | ILA1.11 Million | ILA0.00 | ILA0.00 | — |
| Research & Development | ILA9.15 Million | ILA12.52 Million | ILA17.63 Million | ILA19.47 Million | ILA18.17 Million |
| SG&A | ILA18.46 Million | ILA16.64 Million | ILA5.07 Million | ILA4.27 Million | ILA3.84 Million |
| Total Operating Expenses | ILA40.09 Million | ILA50.80 Million | ILA29.16 Million | ILA24.78 Million | ILA22.93 Million |
| Operating Income | ILA-20.41 Million | ILA-49.69 Million | ILA-29.16 Million | ILA-24.78 Million | ILA-22.93 Million |
| EBITDA | ILA3.92 Million | ILA-57.09 Million | ILA-28.50 Million | ILA-24.07 Million | ILA-21.99 Million |
| EBIT | ILA-147.00K | ILA-58.47 Million | ILA-29.16 Million | ILA-24.78 Million | ILA-22.93 Million |
| Interest Expense | ILA9.07 Million | ILA2.14 Million | ILA2.16 Million | ILA984.00K | ILA1.47 Million |
| Income Before Tax | ILA-9.22 Million | ILA-60.61 Million | ILA-24.95 Million | ILA-27.05 Million | ILA-30.02 Million |
| Income Tax Expense | — | — | ILA-4.21 Million | ILA1.09 Million | ILA911.00K |
| Net Income | ILA-9.22 Million | ILA-60.61 Million | ILA-20.75 Million | ILA-28.14 Million | ILA-30.93 Million |
BioLine RX Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes BioLine RX Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ILA38.91 Million | ILA63.92 Million | ILA76.38 Million | ILA81.39 Million | ILA47.29 Million |
| Total Current Assets | ILA27.10 Million | ILA47.18 Million | ILA52.00 Million | ILA57.40 Million | ILA22.88 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ILA9.13 Million | ILA38.74 Million | ILA40.49 Million | ILA44.15 Million | ILA5.76 Million |
| Net Receivables | ILA3.86 Million | ILA708.00K | ILA721.00K | ILA142.00K | ILA141.00K |
| Inventory | ILA3.15 Million | ILA1.95 Million | ILA197.08K | — | ILA151.71K |
| Property, Plant & Equipment | — | — | — | ILA2.28 Million | ILA2.70 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ILA25.45 Million | ILA50.70 Million | ILA25.54 Million | ILA13.30 Million | ILA25.26 Million |
| Total Current Liabilities | ILA15.41 Million | ILA42.78 Million | ILA10.68 Million | ILA9.72 Million | ILA10.64 Million |
| Long-term Debt | ILA8.96 Million | ILA6.63 Million | ILA8.63 Million | — | ILA2.74 Million |
| Net Debt | ILA4.60 Million | ILA7.34 Million | ILA1.74 Million | ILA-8.34 Million | ILA-9.15 Million |
| Total Stockholder Equity | ILA13.46 Million | ILA13.22 Million | ILA50.84 Million | ILA68.09 Million | ILA22.03 Million |
| Retained Earnings | ILA-399.83 Million | ILA-390.61 Million | ILA-329.99 Million | ILA-305.04 Million | ILA-277.99 Million |
BioLine RX Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how BioLine RX Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ILA-43.87 Million | ILA-22.61 Million | ILA-26.24 Million | ILA-23.57 Million | ILA-23.21 Million |
| Capital Expenditures | ILA54.00K | ILA297.00K | ILA316.00K | ILA97.00K | ILA97.00K |
| Free Cash Flow | ILA-43.93 Million | ILA-22.91 Million | ILA-26.56 Million | ILA-23.67 Million | ILA-23.21 Million |
| Investing Cash Flow | ILA29.37 Million | ILA1.44 Million | ILA4.01 Million | ILA-38.22 Million | ILA16.67 Million |
| Financing Cash Flow | ILA20.66 Million | ILA15.06 Million | ILA20.44 Million | ILA57.75 Million | ILA17.87 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ILA1.14 Million | ILA2.32 Million | ILA2.25 Million | ILA1.50 Million | ILA1.27 Million |
| Depreciation | ILA4.07 Million | ILA1.38 Million | ILA654.00K | ILA703.00K | ILA934.00K |
| Change in Cash | ILA6.18 Million | ILA-6.33 Million | ILA-2.40 Million | ILA-3.84 Million | ILA11.53 Million |
BioLine RX Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track BioLine RX Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 19, 2026 | — | — | — |
| Nov 24, 2025 | 0.00 | 0.00 | — |
| Aug 14, 2025 | 0.00 | 0.00 | — |
| Mar 31, 2025 | 0.00 | -0.01 | +100.00% |
| Nov 25, 2024 | 0.00 | -0.01 | +100.00% |
| Mar 26, 2024 | -0.01 | -0.01 | +0.00% |
| Nov 20, 2023 | -0.02 | -0.01 | -100.00% |
| Aug 30, 2023 | -0.02 | -0.01 | -100.00% |